Cancer Biomarkers Market
Cancer Biomarkers Market - Global Industry Assessment & Forecast
Segments Covered
- By Biomarkers Type Protein Biomarkers, Genetic Biomarkers, Others
- By Cancer Type Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia, Thyroid Cancer, Bladder Cancer, Non-Hodgkin's Lymphoma Kidney Cancer, Others
- By Profiling Technologies Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics
- By Application Research & Development, Prognostics, Risk Assessment, Others
- By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa
Snapshot
Base Year: | 2022 |
Forecast Years: | 2023 - 2030 |
Historical Years: | 2017 - 2021 |
Revenue 2022: | USD 14.08 Billion |
Revenue 2030: | USD 50.47 Billion |
Revenue CAGR (2023 - 2030): | 17.30% |
Fastest Growing Region (2023 - 2030) | Asia Pacific |
Largest Region (2022): | North America |
Customization Offered
- Cross-segment Market Size and Analysis for Mentioned Segments
- Additional Company Profiles (Upto 5 With No Cost)
- Additional Countries (Apart From Mentioned Countries)
- Country/Region-specific Report
- Go To Market Strategy
- Region Specific Market Dynamics
- Region Level Market Share
- Import Export Analysis
- Production Analysis
- Others Request Customization Speak To Analyst
Research Methodology: Cancer Biomarkers Market by Biomarkers Type by Cancer Type by Profiling Technologies by Application by Region - Global Market Assessment, 2021 - 2028
Secondary Research
Primary Research:
The next stage involves the primary research conducted to gather further information and revalidate the data collected from the secondary research. Moreover, primary research is also conducted to identify key players in the market and to gather their market-specific financial information. A typical primary interview fulfills data requirements pertaining to first-hand information global market size, regional and segmental trends, competitive landscape expertise development and market understandings among others.
Data Triangulation and Market Size Estimations
Top-down and bottom-up approaches are used to validate and estimate the market size of the Cancer Biomarkers market. After the determination of the overall market size, the market is divided into various segments and sub-segments. Moreover, these same approaches mentioned above were used to derive and estimate market numbers for mentioned segments/sub-segments in the market. The data was triangulated by employing various data models and statistical techniques to arrive at exact statics and market size for each segment/sub-segment of the market.
FAQ
Frequently Asked Question
What is the global demand for Cancer Biomarkers in terms of revenue?
-
The global Cancer Biomarkers valued at USD 14.08 Billion in 2022 and is expected to reach USD 50.47 Billion in 2030 growing at a CAGR of 17.30%.
Which are the prominent players in the market?
-
The prominent players in the market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific Inc. (US), Qiagen N.V. (Netherlands), Illumina Inc. (US), Bio-Rad Laboratories Inc. (US), Abbott Laboratories (US), Bio Mérieux SA (US), Becton-Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics Inc. (US), Sysmex Corporation (Japan), Hologic Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer Inc. (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems Inc. (US), BioVision Inc. (US), Olink (Sweden), Asuragen Inc. (US), Meso Scale Diagnostics LLC (US), Invivoscribe Inc. (US), Seegene Technologies Inc. (South Korea).
At what CAGR is the market projected to grow within the forecast period?
-
The market is project to grow at a CAGR of 17.30% between 2023 and 2030.
What are the driving factors fueling the growth of the market.
-
The driving factors of the Cancer Biomarkers include
- Rising technological advancements in the development of cancer biomarkers
Which region accounted for the largest share in the market?
-
North America was the leading regional segment of the Cancer Biomarkers in 2022.